Which two markers are associated with monitoring advanced breast cancer progression?

Which two markers are associated with monitoring advanced breast cancer progression?

• A. CA125 and CA 19-9
• B. CA 15-3 and CA 549
• C. CEA and AFP
• D. PSA and hCG

Answer: (B)

In breast cancer management, tracking how the disease behaves over time relies on tumor markers that reflect tumor burden and response to therapy. The two markers typically associated with monitoring advanced breast cancer progression are CA 15-3 and CA 549. CA 15-3 is the most commonly used marker in this context; it is a mucin-1–related antigen that tends to rise with increasing tumor burden and can fall when treatment is effective, making serial measurements useful for assessing progression or response. CA 549 is another related antigen that has been used historically for similar purposes in breast cancer patients, providing additional information about disease activity when monitored alongside CA 15-3. Other marker pairs listed don’t fit this role as well. CA125 is more closely linked to ovarian cancer, CA 19-9 to pancreatic and other GI cancers, CEA is a broad marker that can be elevated in various cancers but is less specific for breast cancer progression, AFP is associated with liver cancer and germ cell tumors, and PSA and hCG are related to prostate and pregnancy/germ cell contexts, not breast cancer progression.

In breast cancer management, tracking how the disease behaves over time relies on tumor markers that reflect tumor burden and response to therapy. The two markers typically associated with monitoring advanced breast cancer progression are CA 15-3 and CA 549. CA 15-3 is the most commonly used marker in this context; it is a mucin-1–related antigen that tends to rise with increasing tumor burden and can fall when treatment is effective, making serial measurements useful for assessing progression or response. CA 549 is another related antigen that has been used historically for similar purposes in breast cancer patients, providing additional information about disease activity when monitored alongside CA 15-3.

Other marker pairs listed don’t fit this role as well. CA125 is more closely linked to ovarian cancer, CA 19-9 to pancreatic and other GI cancers, CEA is a broad marker that can be elevated in various cancers but is less specific for breast cancer progression, AFP is associated with liver cancer and germ cell tumors, and PSA and hCG are related to prostate and pregnancy/germ cell contexts, not breast cancer progression.